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A 3-year retrospective review was undertaken of the use of topiramate in 51 children aged 3–16 years with partial and gener-
alized epilepsies who attended a tertiary referral epilepsy centre in a large children’s hospital. The mean follow-up period was
19 months (range 6–33 months). Twenty-six children (51%) were still receiving topiramate at the time of their last review.
Fifteen children (29%) showed a greater than 50% reduction in their seizure frequency and four children (8%) became seizure
free, three on topiramate monotherapy. The drug appeared to be most effective in children with moderate learning difficulties
with 75% showing an improvement in seizure control compared with 25% of children with normal educational functioning.
Topiramate was withdrawn in 25 patients. The reasons for withdrawal included adverse effects in 20, lack of effect in three and
worsening of seizures in two patients.
Adverse side effects were reported in 57% of the 51 patients. The majority of the side effects were related to behavioural and
cognitive difficulties, with less-common side effects including anorexia, weight loss and headaches.
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INTRODUCTION
Topiramate is a novel anticonvulsant drug with what
appears to be a broad spectrum of activity. The drug
was initially introduced as adjunctive therapy for re-
fractory partial seizures in adults1, but has subse-
quently been reported to be effective in a range of
epilepsy syndromes and seizure types, including in
children2–9. A number of these reports have included
randomized controlled trials (RCTs)4, 5 which are pri-
marily designed to satisfy regulatory requirements in
order that the drug can be licensed. Unfortunately,
RCTs provide little pragmatic information on how the
drug can be used in everyday clinical practice. Thus far
there are limited data on the open use of topiramate in
children outside controlled trials7, 8.
The purpose of this retrospective review of all chil-
dren treated with topiramate over a period of 3 years
in a tertiary referral epilepsy centre is to describe the
effectiveness and safety of the drug and to identify any
specific practical difficulties with its use.
MATERIALS AND METHODS
Data were obtained from the computerized database
of the pharmacy department at Alder Hey Children’s
Hospital. Topiramate was first prescribed in the hos-
pital in June 1996 and data were collected up to
March 1999, representing a period of 33 months. All
prescriptions were initiated or recommended by the
three paediatric neurologists who supervise seizure or
neurology clinics within the hospital. Fifty-one pa-
tients were prescribed topiramate during this period.
Data were collected on seizure type, classifica-
tion of epilepsy, epilepsy syndrome, presence or ab-
sence of learning difficulties, behavioural problems,
the presence or absence of psychiatric illness prior
to treatment with topiramate and treatment with other
antiepileptic drugs.
Information was also collected on the age at which
treatment was commenced, the starting dose, the du-
ration over which the treatment was titrated, the maxi-
mum dose prescribed and the overall duration of treat-
ment.
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Information was not collected on any haematolog-
ical or biochemical data, including serum levels of
topiramate or other antiepileptic drugs, primarily be-
cause such measurements are not usually undertaken
in the routine clinical management of our patients with
epilepsy.
The epilepsy syndromes were classified according
to the International League Against Epilepsy classifi-
cation.
Efficacy was based on seizure frequency with data
obtained from seizure diaries completed by the child’s
parents and carers (and, where appropriate, teachers).
In the absence of seizure diaries, efficacy was more
crudely determined by whether the child and their
usual carers considered that seizure frequency had im-
proved.
The frequency of any hospital admissions because
of increasing seizures, the development of adverse ef-
fects or episodes of convulsive and non-convulsive sta-
tus epilepticus were also recorded.
Safety and tolerability of the drug were based on
spontaneously reported side effects by the child or
their carers.
Statistics were descriptive primarily because of the
relatively small number and the heterogeneous nature
of the study population.
Nineteen patients were reported to have had pre-
existing behaviour problems including attention deficit
hyperactivity disorder (ADHD), temper outbursts and
‘mood swings’. None of these 19 patients had re-
quired formal psychiatric intervention and no patient
was known to have suffered from any previous or con-
current psychiatric illness including depression or psy-
chosis.
RESULTS
Study population
The characteristics of the 51 children are summarized
in Table 1.
Thirty-one children suffered severe, 12 mild to mod-
erate and eight no pre-existing learning difficulties.
Twenty-three patients (45%) had cerebral palsy and
10 patients (20%) were fed via a percutaneous feed-
ing gastrostomy tube.
Prior to the prescription of topiramate, 26 patients
(51%) were experiencing at least daily seizures, 10
(19%) had a seizure frequency of at least one a week
and the remaining 15 (29%) reported a range of seizure
frequencies (the least being about one seizure every
month).
At the time topiramate was introduced, 21 patients
were receiving one, 25 patients two, and five patients
three antiepileptic drugs. Thirty-two patients were re-
Table 1: Demographic features of the 51 patients.
Sex distribution Male/Female 32/19
Behavioural problems 19
Learning difficulties None 8
Mild/moderate 12
Severe 31
Epilepsy diagnosis Symptomatic generalized 30
Idiopathic generalized 5
Lennox–Gastaut syndrome 9
Cryptogenic partial 4
Symptomatic partial 3
ceiving lamotrigine, 19 sodium valproate, 13 pheny-
toin, eight carbamazepine and the remaining 19 chil-
dren were receiving other antiepileptic drugs includ-
ing vigabatrin, a benzodiazepine (clobazam or clon-
azepam) and phenobarbitone.
Two patients were receiving methylphenidate for
ADHD prior to the introduction of topiramate.
The mean duration of follow-up was 19 months
(range 6–33) months.
The median age at which topiramate was introduced
was 8.5 years (range 3.5–16 years).
For all children aged 12 years and over in this
study, topiramate was introduced according to the
data-sheet recommendation. Specific paediatric rec-
ommendations were introduced following a product li-
cence for use as add-on therapy in children advising a
maximum starting dose of 0.5 mg/kg/day and increas-
ing every 2 weeks.
At the time that the majority of our younger pa-
tients were being treated with topiramate, there was
no paediatric licence, and therefore no data-sheet rec-
ommendation for the use of the drug in children under
12 years of age. In these patients the drug was also
introduced at a starting dose of 0.5 mg/kg/day. Al-
though 46 patients, irrespective of age, had their dose
increased every 2 weeks, achieving a target mainte-
nance dose after 6–10 weeks, two patients had a more
rapid escalation over a 3-week period and three had a
slower escalation of the dose over 6 months.
The mean maintenance daily dose was 169 mg,
range 25–500 mg; the one patient who received
500 mg/day weighed 75 kg on her last clinic visit.
The mean maintenance dose, based on body weight,
was 6.7 mg/kg/day (this information was only avail-
able on 36 of the 51 patients because of missing body-
weight data on the remaining 15 patients).
The mean duration of treatment was 10.8 months
(range 3 weeks–32 months). Twenty children received
topiramate for more than 1 year and nine children for
more than 2 years. In 25 children (49%) topiramate
was withdrawn within 6 months of introduction, 20 of
whom developed adverse side effects including be-
haviour and cognitive difficulties (17 children) and
anorexia and weight loss (three children). In two more
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Table 2: Reported adverse effectsa.
Adverse effect Number of children %
Behavioural/cognitive:
Agitation/irritability 7 13
Depression 7 13
Lethargy/no energy 5 10
Visual hallucinations 1 3
Neurological:
Anorexia/weight loss 3 6
Ataxia 3 6
Aphasia 1 2
Other:
Diarrhoea 3 6
Headaches 3 6
a Some patients experienced more than one adverse effect.
children withdrawal was due to the combination of
lack of efficacy and adverse side effects, while the re-
maining three children stopped taking topiramate be-
cause of lack of efficacy.
Twenty-six children (51%) were still receiving top-
iramate at the time of their last clinic review. Twenty-
two of the 51 patients (43%) reported initial improve-
ment in seizure control and of these 22 patients, 15
(29% of the 51 patients) showed a sustained improve-
ment over a period of 4–6 months. In two patients
the drug had to be discontinued because of intolera-
ble side effects despite a marked reduction in seizure
frequency including seizure freedom in one of these
two patients.
Of the 15 patients who showed a sustained response,
five (33%) had symptomatic generalized epilepsy,
three (20%) had Lennox–Gastaut syndrome and three
(20%) had complex partial epilepsy with secondary
generalization.
Four of the 51 patients (8%) became seizure free,
two with a cryptogenic partial epilepsy, one with a
symptomatic generalized epilepsy (secondary to con-
genital toxoplasmosis) and one with a cryptogenic
generalized epilepsy characterized by drop attacks.
It was not possible to analyse efficacy for different
seizure types (i.e. myoclonic, tonic, typical and atypi-
cal absences) because the limited documentation mili-
tated against this specific analysis.
Adverse events were reported by the child, or more
commonly the child’s carers (usually the parents).
Twenty-nine children (57%) reported a total of 39
adverse effects following the prescription of topira-
mate (Table 2). Twenty-nine of these adverse effects
(74%) were behavioural, cognitive or neurological in
nature. Three children aged 9, 13 and 14 years, de-
veloped episodes of unexplained and at times incon-
solable crying and the 14-year-old boy expressed sui-
cidal thoughts and two episodes of self harm; symp-
toms resolved in all three children on discontinua-
tion of topiramate. In most children the behavioural
changes were severe and led to withdrawal of the drug
in 17 children, in spite of an initial reduction in the
daily dose of topiramate.
Anorexia and weight loss developed in three chil-
dren, which persisted after a 25–50% reduction in the
dose of topiramate and eventually led to drug with-
drawal.
No patient was known to have experienced any
symptoms suggesting the development of renal cal-
culi, throughout the period of evaluation.
DISCUSSION
This retrospective audit of a group of children with
chronic epilepsy has demonstrated first that topira-
mate appears to be effective in controlling a range of
seizure types in a number of children, and secondly
that the drug may be associated with significant be-
havioural and cognitive side effects necessitating drug
withdrawal.
It must be emphasized that our study population was
heterogeneous in terms of seizure type, epilepsy syn-
drome, aetiology and cognitive function and in addi-
tion, was comprised of children with previously in-
tractable epilepsy receiving a mean of 1.68 additional
antiepileptic drugs. Most had received the other ‘new’
antiepileptic drugs, including lamotrigine, vigabatrin
and gabapentin, and, therefore, represented a very re-
fractory epilepsy population.
Despite the refractory nature of our patients, four
of our 51 patients (8%) became seizure free for pe-
riods of between 6 and 15 months at the time of their
last review. In three of these children, their other anti-
epileptic drugs (AEDs) could be withdrawn leaving
them seizure free on topiramate monotherapy. In ad-
dition, almost one third showed a significant and sus-
tained improvement in seizure control and in most
of these patients the reduction in seizure frequency
was between 50 and 75%. These findings are simi-
lar to reported results of an open study from a ter-
tiary epilepsy centre where 8% of 39 children with
refractory epilepsy also became seizure free and an
additional 21% showed a greater than 50% reduction
in seizure frequency7. An additional open study re-
ported a greater than 50% reduction in partial seizures
in 28 of 49 (57%) children after 6 months treatment
with topiramate8; in contrast, no patient with a gener-
alized epilepsy syndrome apparently achieved a 50%
reduction in seizure frequency8. However, an earlier
placebo-controlled study in 96 children with refractory
partial seizures reported a responder rate (i.e. a >50%
reduction in seizure frequency) in 39%, with two of the
41 topiramate-treated children (5%) becoming seizure
free4. A controlled study in 98 patients with Lennox–
Gastaut syndrome demonstrated a greater than 50%
reduction in major (i.e. drop attacks and tonic–clonic)
seizures in 15 of the 46 (33%) topiramate-treated pa-
tients5. In addition, in five of these 46 children, drop
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attacks completely ceased in the final 8 weeks of the
double-blind treatment phase.
The controlled trial data4, 5, together with the find-
ings of Uldall and Buchholt7 and the present study,
suggest that topiramate does have a relatively broad
spectrum of action against both partial and generalized
epilepsies. However, there is some evidence that top-
iramate may be more effective in partial rather than
generalized epilepsies (irrespective of whether idio-
pathic or symptomatic origin3, 8), although this could
not be confirmed in the present report because of the
small number of children who were considered to have
a partial epilepsy. As yet, it is also not possible to pro-
vide any definitive information on the response of dif-
ferent seizure types to topiramate because of limited
data in both the open and controlled studies.
Although our study population is relatively small,
it did appear that those children with mild or moder-
ate learning difficulties showed a greater reduction in
seizures compared with those with either severe or no
learning difficulties. There is little or no evidence to
support or refute this observation because most of the
published paediatric data have involved children with
chronic and refractory epilepsy, usually in association
with moderate or severe learning difficulties, and not
in children of normal intellectual ability.
Finally, limited data again precluded the identifica-
tion of whether topiramate used in combination with
any other specific AED proved particularly beneficial
in improving seizure control. An earlier open study
has suggested that the combination of topiramate with
gabapentin, carbamazepine or felbamate may be par-
ticularly effective8.
Twenty-nine of our patients or their carers (57%)
spontaneously reported adverse side effects, the ma-
jority of which (74%) were either behavioural or cog-
nitive in nature and included depression, marked irri-
tability or aggression, psychosis and aphasia. A num-
ber of parents reported that their children appeared
to always be tired or had difficulties with short-term
memory; similar comments were expressed by the
childrens’ teachers, including those children attending
special schools. Anorexia and weight loss were un-
common but severe, and in one child led to the par-
ents requesting discontinuation of the drug despite the
child being seizure free.
The frequency of adverse side effects in this study
is almost identical to two earlier open paediatric stud-
ies which reported an incidence of 54% in 397 chil-
dren, and at least 53% of 49 children8. However, the
type of adverse effects reported was different between
the two studies. In the study by Moreland et al.8,
behavioural and cognitive side-effects predominated
with 53% of patients experiencing ‘decreased cogni-
tion, decreased speech, decreased energy or worsened
behaviour’. Twenty-eight patients in this study also
experienced a reduction in appetite. After 6 months
of treatment, only 34 of the original 49 patients were
available for review; the authors did not stipulate how
many of the remaining 15 patients were no longer tak-
ing topiramate because of lack of efficacy or adverse
effects or both. In contrast to this study, the predomi-
nant side effect in the report by Uldall and Buchholt7
was weight loss (39%) with behavioural and cognitive
difficulties being found in only 21% (sedation/slow
thinking) and ataxia/clumsiness in a further 8%. In this
study by Uldall and Buchholt7, the degree of weight
loss was not specified but was reported to be not severe
and subsided, except in two children who required gas-
tric tube feeding for up to 12 months; no patient with-
drew from topiramate because of weight loss or per-
sisting anorexia.
Weight loss and sedation were the most commonly
reported adverse side effects in the two controlled
studies in partial epilepsy4 and Lennox–Gastaut syn-
drome5, although disturbances of mood, aggressive re-
actions, ‘nervousness’ and other behavioural problems
were also recorded in between 10 and 21% of pa-
tients4, 5. Perhaps surprisingly, no patient in these two
controlled studies withdrew due to any adverse events.
One explanation for the lower incidence of anorexia
and weight loss in our study could be due to the
fact that 20% of our patients were fed exclusively
by a feeding gastrostomy tube and therefore anorexia
would not have been identified. Although the majority
of the patients reported by Uldall and Buchholt7 had
moderate or severe learning difficulties, there was no
information on how many, if any of these children also
were fed through gastrostomies.
In adults, the most frequently reported adverse ef-
fects include behavioural and cognitive difficulties
with an incidence of almost 50% in one retrospec-
tive review of 174 patients3. In this study 90 of the
174 patients had stopped taking the drug at the end of
12 months, many due to adverse effects, and usually
within the first 3–4 months of taking topiramate. Fi-
nally there has also been a report of an acute psychosis
which resolved on discontinuation of the drug10.
Finally, most of our patients who developed adverse
effects failed to improve despite reductions in their
dose of topiramate (often as much as a 50–60% re-
duction) and eventually had to discontinue the drug.
In conclusion, it is clear from both this and earlier
controlled and open studies that topiramate is a potent
antiepileptic drug which appears to have a broad spec-
trum of action in the cryptogenic/symptomatic partial
and generalized epilepsies. Its role in the treatment
of the idiopathic generalized epilepsy syndromes and
primary generalized seizures (i.e. tonic–clonic, typical
absence and myoclonic) is as yet unclear2. However,
the use of topiramate may also be complicated by a
number of adverse side effects, particularly affecting
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behaviour, cognitive function and appetite, which in
many patients, may necessitate premature discontinu-
ation of the drug, in spite of excellent seizure control.
These predominantly neuropsychiatric adverse side-
effects obviously justify caution in using topiramate
in patients with pre-existing learning difficulties or be-
haviour problems (or both)11. However, it is also im-
portant that the use of this drug is carefully consid-
ered on a risk:benefit basis before prescribing it to
children of normal intellectual ability. Although these
adverse effects may potentially be avoided or mini-
mized by a slow titration of the drug (e.g. a starting
dose of 0.5 mg/kg/day increased every 2 weeks up to
an initial target maintenance dose of 4–5 mg/kg/day
achieved over a minimum of 8 weeks), it seems that
there will remain a number of paediatric patients who
are intolerant of the drug. Finally, as in the treatment
of the majority of children with epilepsy, specific care
should be taken when using topiramate with another
AED; future data may or may not identify a particu-
larly effective (or problematic) combination of topira-
mate with another AED.
Finally, although the introduction of topiramate has
undoubtedly offered clinicians an additional treatment
option for improving their patients’ seizure control,
the resulting expansion in available options has cre-
ated a therapeutic dilemma—namely at which stage
topiramate should be prescribed. This dilemma may be
resolved by future comparative studies, including the
NHS R and D-funded Standard and New Antiepileptic
Drugs (‘SANAD’) study.†
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